FDA approved the first generic versions of montelukast sodium (Singulair, Merck) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.
FDA has approved the first generic versions of montelukast sodium (Singulair, Merck) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.
Montelukast is in a class of medications called leukotriene receptor antagonists. It works by blocking the action of leukotrienes, substances in the body that cause the symptoms of asthma and hayfever (allergic rhinitis).
“For people who suffer from chronic health conditions such as asthma and allergies, it is important to have effective and affordable treatment options,” said Gregory P. Geba, MD, MPH, director of the Office of Generic Drugs in FDA’s Center for Drug Evaluation and Research, said in a press release. “The generic products approved today will expand those options for patients.”
Montelukast should not be used for relief of a sudden asthma attack. Some side effects of montelukast can be serious. A healthcare provider should be immediately contacted if any of the following symptoms are experienced: behavior and mood-related changes such as aggression, depression, or hallucinations; feeling of “pins and needles” or numbness in the arms or legs; rash; flu-like symptoms; or severe pain and swelling of the sinuses.
In clinical trials, the most common side effects reported by patients using Singulair included: upper respiratory infection, fever, headache, sore throat, cough, stomach pain, diarrhea, ear ache, flu, runny nose, and sinus infection.
Apotex Inc., Aurobindo Pharma, Endo Pharmaceuticals, Glenmark Generics, Kudco Ireland Inc., Mylan Inc., Roxane Laboratories, Sandoz Inc., Teva Pharmaceuticals Inc., and Torrent Pharmaceuticals have gained FDA approval for generic montelukast tablets. Apotex, Aurobindo, Endo, Kudco, Mylan, Roxane, Sandoz, Teva, and Torrent have received approval for chewable tablets. Teva has received approval for the oral granule form.
Information about the availability of generic montelukast sodium can be obtained from the manufacturers.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.